Zentalis Pharmaceuticals (ZNTL) Income from Continuing Operations (2019 - 2026)
Zentalis Pharmaceuticals' (ZNTL) quarterly Income from Continuing Operations came in at 35352000.0 in Q1 2026, up 26.78% year-on-year from 27885488.48 in Q1 2025, and little changed quarter-over-quarter from 35216000.0 in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 35352000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 26.78% year-over-year to 35352000.0 in Q1 2026; TTM through Mar 2026 was 124133000.0, a 44.63% increase from a year earlier, with the FY2025 full-year figure at 137060000.0, up 17.37% from the prior year.
- Income from Continuing Operations held at 35352000.0 in Q1 2026 per ZNTL's latest filing, from 35216000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 10040000.0 in Q1 2024 and bottomed at 98860000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 48279000.0 (2025), against an average of 49141235.29.
- Across the five-year window, Income from Continuing Operations jumped 116.47% in 2024 and tumbled 580.87% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 48162000.0 in 2022, then decreased by 26.53% to 60939000.0 in 2023, then gained by 22.1% to 47472000.0 in 2024, then rose by 25.82% to 35216000.0 in 2025, then declined by 0.39% to 35352000.0 in 2026.
- Per Business Quant, the three latest ZNTL Income from Continuing Operations figures stand at 35352000.0 (Q1 2026), 35216000.0 (Q4 2025), and 26691000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Zentalis Pharmaceuticals | 302.14 Mn | 302.14 Mn | - | -35.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.35 Mn |
| Dec 31, 2025 | -35.22 Mn |
| Sep 30, 2025 | -26.69 Mn |
| Jun 30, 2025 | -26.87 Mn |
| Mar 31, 2025 | -48.28 Mn |
| Dec 31, 2024 | -47.47 Mn |
| Sep 30, 2024 | -40.16 Mn |
| Jun 30, 2024 | -88.28 Mn |
| Mar 31, 2024 | 10.04 Mn |
| Dec 31, 2023 | -60.94 Mn |
| Sep 30, 2023 | -55.54 Mn |
| Jun 30, 2023 | -98.86 Mn |
| Mar 31, 2023 | -60.95 Mn |
| Dec 31, 2022 | -48.16 Mn |
| Sep 30, 2022 | -52.13 Mn |
| Jun 30, 2022 | -63.05 Mn |
| Mar 31, 2022 | -57.49 Mn |
| Dec 31, 2021 | -48.26 Mn |
| Sep 30, 2021 | -10.49 Mn |
| Jun 30, 2021 | -55.06 Mn |